

167

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gilles H Tapolsky et al.

Title: Pharmaceutical Carrier Device Suitable for Delivery of Pharmaceutical Compounds to Mucosal Surfaces

Docket No.: 1195.335US1

Filed: April 29, 1998

Examiner: Edward J. Webman



Serial No.: 09/069,703

Due Date: September 1, 2005

Group Art Unit: 1617

**MS Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

☒ Return postcard.

☒ Response Under 37 CFR 1.111 (9 pgs.).

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

By: 


Atty: A. James Nelson

Reg. No. 28,650

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1 day of September, 2005.

**CANDIS BUENDING**

Name

  
Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)

S/N 09/069,703



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Gilles H Tapolsky et al.	Examiner: Edward J. Webman
Serial No.:	09/069,703	Group Art Unit: 1617
Filed:	April 29, 1998	Docket No.: 1195.335US1
Title:	PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES	

---

**RESPONSE UNDER 37 CFR § 1.111**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In reply to the Office Action mailed June 1, 2005, and pursuant to 37 C.F.R. § 1.111, Applicants respectfully request reconsideration and reexamination of the subject application in view of the following remarks, which begin at page 7.

No amendments are presented. A clean copy of the claims is included to facilitate discussion.